Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 11/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941693 | 0.88 | MEN1 (0.63) | LRRK2MEN1KMT2ASGMS2MET | |
| SCHEMBL4939255 | 0.88 | NPC1 (0.63) | LRRK2MEN1KMT2ASGMS2MET | |
| SCHEMBL4943478 | 0.86 | MET (0.74) | LRRK2MEN1KMT2ASGMS2MET | |
| SCHEMBL4937063 | 0.86 | MET (0.74) | LRRK2MEN1KMT2ASGMS2MET | |
| SCHEMBL13372613 | 0.83 | LRRK2 (0.52) | LRRK2MEN1KMT2AMETNR1H4 | |
| SCHEMBL4940840 | 0.82 | SGMS2 (0.61) | MEN1KMT2ASGMS2MET | |
| SCHEMBL1647521 | 0.82 | LRRK2 (1.00) | LRRK2MEN1KMT2ASGMS2 | |
| SCHEMBL15943342 | 0.82 | LRRK2 (0.77) | LRRK2MEN1KMT2ASGMS2LMNA | |
| SCHEMBL22837809 | 0.82 | MELK (0.63) | LRRK2MEN1KMT2ASGMS2LMNA | |
| SCHEMBL4940769 | 0.81 | SGMS2 (0.66) | LRRK2MEN1KMT2ASGMS2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618285-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-1853570-B1 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20080182857-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182857-A1 | Triazole Derivatives | HSP90AB1, HSP90AA1, HSP90B1 | LRRK2 982/4885MEN1 4447/4885KMT2A 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.